drugset

drugset / Trial / NCT00925275

Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors

NCT00925275 ↗

Phase 1 Completed 9 enrolled Cellectar, Inc

Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry and pharmacokinetics of I-131-CLR1404.

Timeline

Start: 2009-06
Primary completion: 2010-02
Completion: 2010-02

Publications

Grudzinski JJ, Titz B, Kozak K, Clarke W, Allen E, Trembath L, Stabin M, Marshall J, Cho SY, Wong TZ, Mortimer J, Weichert JP. A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety. PLoS One. 2014 Nov 17;9(11):e111652. doi: 10.1371/journal.pone.0111652. eCollection 2014.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	I-131-CLR1404	Small molecule	370 mbq	Intravenous

Indications